Clinical trials and animal studies of HIV remi

Quote:

---

Clinical trials and animal studies of HIV remission approaches reported outcomes of interventions designed to maintain HIV viral suppression or remission after ART was paused. When ART is paused in an HIV remission study it is called an analytical treatment interruption (ATI) .

In one study, researchers infected 16 infant monkeys with the simian version of HIV (SHIV), then placed them into three different treatment groups, each including ART with various combinations of the investigational HIV drug leronlimab and the HIV bNAbs called PGT121-LS and VRC07-523-LS.

After 27 weeks of treatment , the research team conducted an ATI and observed outcomes by treatment group.

Animals that received ART and both HIV bNAbs experienced rapid rebound of detectable SHIV.

Two of 6 animals that received ART and leronlimab remained free of detectable virus through 20 weeks after ATI.

All of the animals that received ART, leronlimab and the two HIV bNAbs remained free of detectable virus at the time of abstract submission, 15 weeks after ATI.

Monitoring and assessment of monkeys’ SHIV reservoirs is ongoing, and further studies are warranted to understand the effects observed, according to the authors.

https://www.niaid.nih.gov/news-events/hivr4p-...highlights

---

Then on to the next conference later this month with this abstract using leronlimab
https://tnprc.tulane.edu/nhp-aids

Short-term Combination Immunotherapy with bNAbs and CCR5 Blockade Mediates ART-Free Viral Control in Infant Rhesus Macaques

Wednesday, 23rd October - 14:00: (Grand Ballroom (Westin New Orleans)) - Oral

excerpt 1
"0/8 animals in group 3 (ART + bNAbs + Leronlimab) have rebounded at the time of abstract submission (27 weeks post ATI); cell-associated viral DNA from PBMC and lymph node was also undetectable in this group."

excerpt2
"Conclusions: Finding a treatment that can prevent reservoir establishment and spread after the first 48 hours has been elusive. The results of this study suggest that the combination of ART, bNAbs, and CCR5 blockade via Leronlimab synergize in an undefined mechanism to prevent further seeding of the reservoir early after infection, and may even permanently reduce it. Further studies are warranted to study this combinatorial effect in more detail. "

There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.